Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection

American Journal of Transplantation

Volumn 5, Issue 3, 2005, Pages 517-528

  Campbell, Lacey G ^a   Ramachandran, Sabarinathan ^a   Liu, Wei ^a   Shipley, Michael ^a   Itohara, Shigeyoshi ^b   Rogers, Joseph G ^a   Moazami, Nader ^a   Senior, Robert M ^a   Jaramillo, Andrés ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Allograft rejection; Dendritic cells; Heart; Matrix metalloproteinase 2; Matrix metalloproteinase 9; T cells

Indexed keywords

GELATINASE A; GELATINASE B;

ALLOIMMUNITY; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CARDIAC GRAFT REJECTION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME DEFICIENCY; FIBROSIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; ZYMOGRAPHY;

ANIMALS; COLLAGEN; DENDRITIC CELLS; GRAFT REJECTION; HEART TRANSPLANTATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MYOCARDIUM; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 14644416034     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00744.x     Document Type: Article

References (46)

1. Orosz CG. Local cellular immunology of experimental transplant vascular sclerosis. Clin Transplantation 1996; 10: 100-103.
2. Dengler TJ, Pober JS. Cellular and molecular biology of cardiac transplant rejection. J Nucl Cardiol 2000; 7: 669-685.
3. Joosten SA, van Koten C, Paul LC. Pathogenesis of chronic allograft rejection. Transpl Int 2003; 16: 137-145.
4. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4.
5. Nagase H, Woessner JF, Jr. Matrix Metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
6. Shapiro SD, Senior RM. Matrix Metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999; 20: 1100-1102.
7. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
8. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-540.
9. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-579.
10. Opdenakker G, Van den Steen PE, Dubois B et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-859.
11. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
12. Graesser D, Mahooti S, Madri JA. Distinct roles for matrix metalloproteinase-2 and α4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 109: 121-131.
13. Dubois B, Masure S, Hurtenbach U et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999; 104: 1507-1515.
14. Biddison WE, Kubota R, Kawanishi T et al. Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol 1997; 159: 2018-2025.
15. Yakubenki VP, Lobb RR, Plow EF, Ugarova TP. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon α4β1-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res 2000; 260: 73-84.
16. Miltenburg AM, Lacraz S, Welgus HG, Dayer JM. Immobilized anti-CD3 antibody activates T cell clones to induce the production of interstitial collagenase, but not tissue inhibitor of metalloproteinases, in monocyte THP-1 cells and dermal fibroblasts. J Immunol 1995; 154: 2655-2667.
17. Mach F, Schonbeck U, Fabunmi RP et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154: 229-238.
18. Schonbeck U, Mach F, Sukhova GK et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture. Circ Res 1997; 81: 448-454.
19. Ito A, Mukaiyama A, Itoh Y et al. Degradation of interleukin-1β by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-14660.
20. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289: 1202-1206.
21. McQuibban GA, Butler GS, Gong JH et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276: 43503-43508.
22. Corry DB, Rishi K, Kanellis J et al. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP-2-deficiency. Nat Immunol 2002; 3: 347-353.
23. Suzuki JI, Isobe M, Kawauchi M, Endoh M, Amano J, Takamoto S. Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transplant Int 2000; 13: 106-113.
24. Tsukioka K, Suzuki JI, Kawauchi M et al. Expression of membrane-type 1 matrix metalloproteinase in coronary vessels of allotransplanted primate hearts. J Heart Lung Transplant 2000; 19: 1193-1198.
25. Ermolli M, Schumacher M, Lods N, Hammoud M, Marti HP. Differential expression of MMP-2/MMP-9 and potential benefit of an MMP inhibitor in experimental acute kidney allograft rejection. Transpl Immunol 2003; 11: 137-145.
26. Laplante A, Liu D, Demeule M et al. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection. Transpl Int 2003; 16: 262-269.
27. Rodrigo E, Lopez-Hoyos M, Escallada R et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy. Nephrol Dial Transplant 2000; 15: 2041-2045.
28. Yamani MH, Starling RC, Young JB et al. Acute vascular rejection is associated with up-regulation of vitronectin receptor (αvβ3), increased expression of tissue factor, and activation of the extracellular matrix metalloproteinase induction system. J Heart Lung Transplant 2002; 21: 983-989.
29. Trello CA, Williams DA, Keller CA, Crim C, Webster RO, Ohar JA. Increased gelatinolytic activity in bronchoalveolar lavage fluid in stable lung transplant recipients. Am J Respir Crit Care Med 1997; 156: 1978-1986.
30. Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-α and interleukin-10. J Heart Lung Transplant 2001; 20: 1144-1151.
31. Coker ML, Thomas CV, Clair MJ et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 1998; 274: H1516-H1523.
32. Coker ML, Zellner JL, Crumbley AJ, Spinale FG. Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy. Ann N Y Acad Sci 1999; 878: 559-562.
33. Etoh T, Joffs C, Deschamps AM et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001; 281: H987-H994.
34. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997; 272: 22389-22392.
35. Vu TH, Shipley JM, Bergers G et al. MMP-9/gelatinase B is key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 90: 411-422.
36. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. Transplantation 1973; 16: 343-350.
37. ΔΔCT method. Methods 2001; 25: 402-408.
38. Fukao T, Frucht DM, Yap G, Gadlins M, O'Shea JJ, Koyasu S. Inducible expression of stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol 2001; 166: 4446-4455.
39. McMillan SJ, Kearley J, Campbell JD et al. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol 2004; 172: 2586-2594.
40. Wang M, Qin X, Mudgett JS, Ferguson TA, Senior RM, Welgus HG. Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Proc Natl Acad Sci U S A 1999; 96: 6885-6889.
41. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61: 237-242.
42. Kobayashi Y, Matsumoto M, Kotani M, Makino T. Possible involvement of matrix metalloproteinase-9 in Langerhans cell migration and maturation. J Immunol 1999; 163: 5989-5993.
43. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 1995; 27: 2177-2189.
44. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999; 277: H777-H787.
45. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996; 155: 13-21.
46. Ratzinger G, Stoitzner P, Ebner S et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 2002; 168: 4361-4371.